Kimberly-Clark is laying down $40bn to buy Kenvue in a massive deal that has puzzled some investors, as the maker of Tylenol struggles with weak sales, lawsuits and White House attacks linking its painkiller to autism.

Shares of Kimberly-Clark dropped sharply after the Monday announcement as stockholders scrutinised the 46 percent premium being paid for the former Johnson & Johnson unit that has had a turbulent year.

Kenvue ousted its CEO in July, and has been under fire from United States President Donald Trump over unproven claims that Tylenol use during pregnancy can cause autism in children.

Kenvue shares, which had dropped sharply since Trump’s comments, jumped 17.5 percent on Monday. Many investors have been awaiting a sale of all or parts of the company for months, following ac

See Full Page